OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 10, 2024
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.
January 09, 2024
In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.
January 08, 2024
Webinar Date/Time: Tue, Jan 30, 2024 9:00 AM EST
Webinar Date/Time: Thu, Jan 25, 2024 11:00 AM EST
Webinar Date/Time: Tue, Jan 30, 2024 11:00 AM EST
January 05, 2024
MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
January 04, 2024
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
January 03, 2024
Novel molecular glues are transforming targeted protein degradation.
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.